GLP-1 single agonist vs. GLP-1/GIP dual agonist: Why is tepote better?

In recent years, GLP-1 receptor agonists have become the core drugs for the management of obesity and type 2 diabetes. Among them, GLP-1 single agonists such as semaglutide ( Wegovy , Ozempic ) have been widely used and have shown good weight loss and glucose control effects. However, as the first GLP-1/GIP dual agonist, telopoietin ( Mounjaro/Zepbound ) not only surpasses semaglutide in weight loss effect, but also excels in tolerability and metabolic improvement .

So, what is the essential difference between GLP-1 monoagonists and GLP-1/GIP dual agonists? Why is tepote better for weight loss? This article will analyze in detail why tepote has become the strongest GLP-1 weight loss drug at present through its mechanism of action, clinical research data, and side effect comparison.

 

1. GLP-1 single agonist vs. GLP-1/GIP dual agonist: fundamental difference in mechanism of action

( 1 ) GLP-1 receptor agonist (semaglutide)

Main functions :

       Reduce appetite : Act on the appetite center of the hypothalamus in the brain, reduce hunger, and make people actively reduce food intake.

       Delays gastric emptying : Increases satiety and allows food to stay in the stomach longer, thereby reducing the amount of food eaten.

       Promote insulin secretion and lower blood sugar : suitable for people with diabetes and metabolic abnormalities.

limitation :

       It mainly relies on reducing appetite, with limited effects on fat breakdown and energy expenditure , resulting in slower weight loss in some patients.

       Gastrointestinal side effects (nausea, vomiting, diarrhea) are strong and some patients may find it difficult to tolerate them for a long time.

( 2 ) GLP-1/GIP dual agonist (tepoltide)

In addition to the effects of GLP-1 , GIP receptor agonism brings additional advantages :

       It promotes fat decomposition, increases metabolic rate , acts directly on fat cells, accelerates fat oxidation, and makes weight loss faster and more stable.

       Enhance insulin sensitivity and reduce insulin resistance, which is more beneficial for patients with prediabetes and diabetes.

       Reduce the gastrointestinal side effects of GLP-1 drugs , improve patient tolerance, and improve long-term compliance.

Conclusion : GLP-1 mainly relies on reducing calorie intake , while the GIP effect of telportin can also promote fat consumption, improve metabolism, and enhance tolerance , thereby optimizing the weight loss effect from multiple aspects.

 

2. Comparison of clinical research data: telpotide vs. semaglutide

Research

Tipollution ( GLP-1/GIP dual agonist)

Semaglutide ( GLP-1 monoagonist)

Weight loss (average)

22.5% weight loss after 72 weeks ( SURMOUNT-1 study)

16.9% weight loss after 68 weeks ( STEP-1 study)

Proportion of people with weight loss ≥ 20%

57%

36%

Maximum weight loss

Up to 27%

Up to 18%

Target Group

Obese and overweight patients with metabolic abnormalities

Obese and diabetic patients

📌 Data Analysis :

       The average weight loss of tebuconazole in the same period was 5.6% higher than that of semaglutide , and the long-term weight loss effect was stronger.

       More than 57% of patients lost more than 20% of their body weight , compared with only 36% for semaglutide.

       Tipoline not only reduces appetite, but also accelerates fat decomposition, making it the strongest weight loss drug currently approved by the FDA .

 

3. Side effect comparison: Which one is better tolerated?

Side effect category

Tipollution ( GLP-1/GIP dual agonist)

Semaglutide ( GLP-1 monoagonist)

nausea

31%

44%

Vomit

18%

twenty four%

diarrhea

twenty one%

30%

constipate

14%

17%

📌 in conclusion :

       The GIP effect of tepoxetine can reduce the common gastrointestinal side effects of GLP-1 drugs and improve patient tolerance.

       Compared with semaglutide, telpotide has lower incidences of nausea, vomiting, and diarrhea, and is easier to maintain during long-term use.

 

4. Telbutide vs. semaglutide: Which one is better for you?

📌 If your goal is maximum weight loss ( >20% body weight loss)

Telbutaline is currently the strongest choice , with a weight loss of up to 22.5%-27% , far exceeding semaglutide.

📌 If you have had difficulty adhering to GLP-1 medication due to side effects (nausea, vomiting)

The GIP effect of tepoxetine can reduce gastrointestinal side effects, improve tolerance , and make it more suitable for long-term use.

📌 If your main concern is sugar control (such as diabetics)

Both semaglutide and telpotide can effectively lower blood sugar , but telpotide has a stronger effect on improving insulin sensitivity and is more advantageous for patients with prediabetes.

💡 Final conclusion : Telpotide is superior to semaglutide in weight loss effect, tolerability and metabolic improvement, and is the strongest FDA- approved GLP-1 weight loss drug on the market.

 

🛒Mounjaro 2.5mg *2 sticks / box*2

🛒Mounjaro 5mg *2pcs / box

 

🛒Mounjaro 7.5mg *2pcs / box

🛒Mounjaro 10mg *2pcs / box

 

🛒Mounjaro 12.5mg *2pcs / box

🛒Mounjaro 15mg *2pcs / box

 

Eli Lilly's official website introduces telportipeptide ( EN )

 

--------------------------------

Welcome to add customer service to get new customer discount

WeChat

Customer Service 1AobMedical

Customer Service 2Aob202404

 

WhatsApp

Kent : +1 6462071346

Asakusa makeup: +81 8070566715

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.